Not a problem. EMD is still an amazingly promising opportunity for Bisantrene, but before it can be pursued we need more data that will make clinicians feel comfortable PET screening their patients before they fail their current treatment. I am feeling hopeful the MD Anderson study we are supporting will do this, but in the meantime we can work on other areas. The great thing about Bisantrene is we are not lacking great opportunities to pursue.
Not a problem. EMD is still an amazingly promising opportunity...
-
- There are more pages in this discussion • 131 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
